title: Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
authors.affiliation: The Preston Robert Tisch Brain Tumour Centre at Duke University Medical Centre, Department of Neurosurgery, DUMC Box 3624, Durham, NC 27710, USA.
authors.forename: Annick
authors.initials: A
authors.lastname: Desjardins
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000191:economics* / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000628:therapy*; D059248:Chemoradiotherapy / Q000191:economics*; D003606:Dacarbazine / Q000031:analogs & derivatives*; D016527:Drug Costs; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000191:economics* / Q000628:therapy*; D006801:Humans; D008297:Male; D011788:Quality of Life
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine